image
Healthcare - Biotechnology - NASDAQ - US
$ 4.51
-1.31 %
$ 213 M
Market Cap
-2.59
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CADL stock under the worst case scenario is HIDDEN Compared to the current market price of 4.51 USD, Candel Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CADL stock under the base case scenario is HIDDEN Compared to the current market price of 4.51 USD, Candel Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CADL stock under the best case scenario is HIDDEN Compared to the current market price of 4.51 USD, Candel Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CADL

image
$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-33.4 M OPERATING INCOME
13.08%
-55.2 M NET INCOME
-45.44%
-27 M OPERATING CASH FLOW
21.09%
-16 K INVESTING CASH FLOW
94.29%
94.3 M FINANCING CASH FLOW
78017.36%
0 REVENUE
0.00%
-8.14 M OPERATING INCOME
7.03%
-14.1 M NET INCOME
-32.19%
-5.81 M OPERATING CASH FLOW
11.55%
-3 K INVESTING CASH FLOW
0.00%
91.9 M FINANCING CASH FLOW
5380.80%
Balance Sheet Candel Therapeutics, Inc.
image
Current Assets 104 M
Cash & Short-Term Investments 103 M
Receivables 0
Other Current Assets 1.15 M
Non-Current Assets 3.06 M
Long-Term Investments 0
PP&E 2.73 M
Other Non-Current Assets 329 K
96.06 %Total Assets$106.9m
Current Liabilities 37.5 M
Accounts Payable 237 K
Short-Term Debt 10.5 M
Other Current Liabilities 26.8 M
Non-Current Liabilities 3.01 M
Long-Term Debt 407 K
Other Non-Current Liabilities 2.6 M
25.80 %66.19 %6.42 %Total Liabilities$40.5m
EFFICIENCY
Earnings Waterfall Candel Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 33.4 M
Operating Income -33.4 M
Other Expenses 21.8 M
Net Income -55.2 M
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)000(33m)(33m)(22m)(55m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
0.00% ROE
0.00%
0.00% ROA
0.00%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Candel Therapeutics, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)202020202021202120222022202320232024202420252025
Net Income -55.2 M
Depreciation & Amortization 990 K
Capital Expenditures -16 K
Stock-Based Compensation 5.31 M
Change in Working Capital 346 K
Others 22 M
Free Cash Flow -27 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Candel Therapeutics, Inc.
image
CADL has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 19
6. Ownership
Insider Ownership Candel Therapeutics, Inc.
image
Sold
0-3 MONTHS
1.23 M USD 5
3-6 MONTHS
1.56 M USD 5
6-9 MONTHS
486 K USD 1
9-12 MONTHS
855 K USD 5
Bought
0 USD 0
0-3 MONTHS
7.5 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409 Candel Therapeutics Inc (NASDAQ:CADL) shared promising results from a Phase 1b clinical trial testing its experimental cancer therapy, CAN-2409, in patients with newly diagnosed high-grade glioma—a particularly aggressive form of brain cancer. The study, published in Neuro-Oncology, found that CAN-2409, when combined with the immunotherapy drug nivolumab and standard treatments like surgery, radiation, and chemotherapy, was well tolerated and showed signs of boosting the immune system's response to tumors. proactiveinvestors.com - 1 month ago
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care globenewswire.com - 1 month ago
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI Candel Therapeutics Inc (NASDAQ:CADL) earlier this week shared updated clinical data from a Phase 2a study evaluating its immunotherapy candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said the study enrolled patients who had exhausted standard treatment options, including chemotherapy and checkpoint inhibitors. proactiveinvestors.com - 1 month ago
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday that its experimental immunotherapy, CAN-2409, demonstrated prolonged median overall survival in a Phase 2a clinical trial for patients with advanced non-small cell lung cancer (NSCLC) who had not responded to immune checkpoint inhibitors (ICI). Patients receiving CAN-2409 showed a median overall survival of 24.5 months, exceeding historical survival rates for this population, the company said. proactiveinvestors.com - 1 month ago
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment NEEDHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final survival data from a phase 2a clinical trial of CAN-2409 in patients with stage III/IV NSCLC, inadequately responding to ICI treatment. mOS was 24.5 months in 46 evaluable patients receiving 2 courses of CAN-2409 (per protocol population; cohort 1 and 2) and 21.5 months in evaluable patients from cohort 2 (n=41) that presented with progressive disease at baseline, despite ICI treatment. mOS in patients with progressive disease despite ICI treatment, was 9.8-11.8 months in other studies, including those with standard of care of docetaxel chemotherapy, which has a very poor prognosis, did not exceed 12 months in other published studies.(1, 2 ) This final analysis included extended follow-up data (1 year after the previous data cut) with a median follow up time for the per protocol population of 32.4 months. Data showed a sizable percentage of patients with survival exceeding 24 months, evidence of a long tail of survival, with 37% of patients with progressive disease despite treatment with ICI alive 2 years after CAN-2409 administration. globenewswire.com - 1 month ago
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now Candel Therapeutics (CADL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com - 1 month ago
Candel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409 Candel Therapeutics Inc (NASDAQ:CADL) announced that it has partnered with IDEA Pharma to advance the commercialization of its lead immunotherapy candidate CAN-2409. The collaboration follows positive Phase 3 data showing CAN-2409 significantly improved disease-free survival in patients with intermediate-to-high-risk localized prostate cancer. proactiveinvestors.com - 1 month ago
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409 NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, together with IDEA Pharma, a Division of SAI MedPartners (IDEA), a pioneering biopharmaceutical strategy consultancy, today announced a strategic commercial partnership. globenewswire.com - 1 month ago
Candel Therapeutics appoints cancer immunology expert to research advisory board Candel Therapeutics Inc (NASDAQ:CADL) said on Tuesday it has appointed Dr Elizabeth Jaffee to its research advisory board. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology and Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. proactiveinvestors.com - 1 month ago
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D. NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Elizabeth M. Jaffee, M.D., to the Company's Research Advisory Board (RAB). Dr. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the RAB, which is important in light of the Company's focus on borderline resectable pancreatic cancer. globenewswire.com - 1 month ago
Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it is preparing to submit a Biologics License Application (BLA) for its lead candidate, CAN-2409, in prostate cancer, as the company pushes forward with late-stage development across multiple cancer indications. CEO Paul Peter Tak said the company enters 2025 “well-resourced with a clear direction,” focusing on regulatory readiness for CAN-2409's potential approval. proactiveinvestors.com - 1 month ago
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. globenewswire.com - 1 month ago
8. Profile Summary

Candel Therapeutics, Inc. CADL

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 213 M
Dividend Yield 0.00%
Description Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Contact 117 Kendrick Street, Needham, MA, 02494 https://www.candeltx.com
IPO Date July 27, 2021
Employees 38
Officers Dr. Seshu Tyagarajan Ph.D. Chief Technical & Development Officer Ms. Ileen B. Winick Chief People Officer Dr. Francesca Barone M.D., Ph.D. Chief Scientific Officer Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. President, Chief Executive Officer & Director Ms. Susan Stewart J.D., L.L.M. Chief Regulatory Officer Mr. Charles Schoch Interim Chief Financial Officer, Principal Accounting Officer, Treasurer & Secretary Dr. William Garrett Nichols M.D., M.S. Chief Medical Officer